A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa [levodopa/carbidopa] Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations.

Trial Profile

A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa [levodopa/carbidopa] Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Levodopa/carbidopa (Primary) ; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 28 Jan 2016 Pooled exploratory post-hoc analysis of 3 trials including this trial and 2 other studies [see CTP 700027941 and 70017544] were published in the Movement Disorders.
    • 16 Dec 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 16 Dec 2011 Actual patient number is 35 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top